Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 541 to 555 of 2580 results for methods

  1. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development Reference number: GID-TA10393 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development Reference number: GID-TA10553 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]

    In development Reference number: GID-TA11657 Expected publication date:  07 April 2027

    Technology appraisal guidance
    In development

  4. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]

    In development Reference number: GID-TA11813 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    In development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development Reference number: GID-TA11100 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    In development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ensitrelvir for treating COVID-19 [ID6231]

    In development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Insulin efsitora alfa for treating type 2 diabetes ID6499

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  13. Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]

    Awaiting development Reference number: GID-TA11606 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development